000			02596nam a22002177a 4500
008			220830b2022 |||||||| |||| 00| 0 eng d
020			_a9789390780136
082			_a616.2414 DUG-Y
100			_aDugyala, Yashwanth Kumar
245			_aVaccines and treatment of COVID-19 / _cYashwanth Kumar Dugyala and K. S. S. N. Neelima
260			_aIndia _bRandom Publications _c2022
300			_a315 p.
365			_aINR _b2395.00.
440			_a
500			_ascientist the world have developed treatments and vaccines for the new corona virus disease know as COVID19. several companies are working on antiviral drugs. some of which are already in use against other illnesses, to treat people who have COVID 19.having safe and effective COVID19 vaccines available will be an important tool to help with the long term management of COVID-19.Health Canada is prioritizing the review of all COVID-19 drugs and vaccines. several medicinal products have been studied or are currently undergoing clinical trials to assess their safety and efficacy as potential agents for pharmaceutical prophylaxis or treatment of COVID-19. These include corticosteroids, the antiviral nucleotide analogue remdesivir, systemic interferons, monoclonal antibodies against components of the immune system such as interleukin-6,other immune modulators, and monoclonal antibodies against components of SARS cov-2. clinical trials of therapeutic interventions for covid-19 have focused on adult patients, and therefore limited data exist on the treatment of covid-19 in children. A recent announcement by the university of oxford that researchers there had started testing a vaccine against the novel coronavirus disease has raised hopes. over the last few weeks, there have also been somewhat conflicting reports about the performance of a drug candidate, remdesivir, while Israel has announced a breakthrough in another possible line of treatment, that with antibodies. this book is discusses vaccination and vaccine development historically and in the context of the covid-19 pandemic. it describes the process of traditional vaccine development, summarizes the biology and immune response demonstrated from previous coronavirus infections and SARS cov-2. it outlines the challenges associated with vaccine production in a pandemic and examines the various platform being utilized for COVID-19 vaccine candidates.
650			_aCOVID-19 (Disease)--Treatment
650			_aCOVID-19 (Disease)--Vaccination
650			_aAnti-infective agents
650			_aDrugs--Physiological effect
700			_aNeelima, K. S. S. N.
999			_c80417 _d80417